

COVITREM-1 - Prognostic value of measuring the activation pathway for Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) in patients hospitalised due to COVID-19

Head :GIBOT Sébastien

Last update : 05/06/2021 | Version : 1 | ID : 73586

General

Identification

Detailed name	Prognostic value of measuring the activation pathway for Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) in patients hospitalised due to COVID-19
---------------	---

Sign or acronym	COVITREM-1
-----------------	------------

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	NCT04544891
--	-------------

General Aspects

Medical area	Anesthesiology ? Intensive care Infectious diseases
--------------	--

Study in connection with Covid-19	Yes
-----------------------------------	-----

Pathology (details)	patients hospitalised due to Covid-19
---------------------	---------------------------------------

Keywords	biomarker, COVID-19
----------	---------------------

Scientific investigator(s) (Contact)

Name of the director	GIBOT
----------------------	-------

Surname	Sébastien
---------	-----------

Email	s.gibot@chru-nancy.fr
-------	-----------------------

Organization	Nancy Regional University Hospital
--------------	------------------------------------

Collaborations

Participation in projects, networks and consortia	Yes
---	-----

Funding	
Funding status	Public
Details	BPI France
Governance of the database	
Sponsor(s) or organisation(s) responsible	Nancy Regional University Hospital
Organisation status	Public
Presence of scientific or steering committees	Yes
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is made on the basis of:	Another treatment or procedure
Database recruitment is carried out as part of an interventional study	No
Database objective	
Main objective	Evaluate the prognostic value of initial TREM-1 activation (first measurement collected) on clinical deterioration in patients hospitalised due to COVID-19 in medical, emergency and intensive care departments
Inclusion criteria	<p>Patients aged over 18 years</p> <p>Hospitalised for less than 3 days for any reason whatsoever, but screened for Covid-19. SARS-CoV-2 infection should be "probable" or "confirmed" according to the definition published on 3 April by Santé Publique France (French Public Health Agency): laboratory confirmation (by positive RT-PCR further to nasopharyngeal sample or any other</p>

sample and/or positive serology indicating infection) or by a composite endpoint combining characteristic pulmonary impairment upon imaging and clinical/laboratory effects suggesting viral infection (including: fever, cough, chest pain, and biological inflammatory syndrome, lymphopenia, elevated liver enzymes).

Registered with a social security scheme or a beneficiary of such a scheme

The patient or their representative will have received information on the study and signed the emergency informed consent/inclusion form in compliance with Article L.1122-1-3 of the French Public Health Code (CSP)

Population type

Age

Adolescence (13 to 18 years)
 Adulthood (19 to 24 years)
 Adulthood (25 to 44 years)
 Adulthood (45 to 64 years)
 Elderly (65 to 79 years)
 Great age (80 years and more)

Population covered Sick population

Pathology J96 - Respiratory failure, not elsewhere classified

Gender Male
 Woman

Geography area National

Data collection

Dates

Date of first collection (YYYY or MM/YYYY) 2020

Size of the database

Size of the database (number of individuals) [1000-10 000[individuals

Details of the number of individuals 1009

Data

Database activity Current data collection

Type of data collected Clinical data

Biological data

Clinical data (detail)	Direct physical measures
Presence of a biobank	Yes
Contents of biobank	Serum Plasma DNAc/RNA _m
Health parameters studied	Health event/morbidity Health event/mortality
Procedures	
Participant monitoring	Yes
Monitoring procedures	Monitoring by contact with the participant (mail, e-mail, telephone etc.)
Links to administrative sources	No
Promotion and access	
Promotion	
Access	